An innovative initiative led by Servier Canada to help hypertensive patients
All the news from Servier Group
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting
Servier establishes strategic research alliance with Harvard University
Servier and Geneuro to present six-month results from CHANGE-MS phase 2b study in multiple sclerosis at MSParis2017
Servier awards its Research Fellowship to a young European researcher in cardiology
Servier and Institut Curie extend duration and scope of partnership in fight against cancer
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
Servier and ILTOO Pharma sign a license option agreement for the clinical development and commercialization of low-dose interleukin-2 for the treatment of autoimmune diseases
Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics